Epigenetic Activation of lncRNA MIR155HG Mediated by Promoter Hypomethylation and SP1 is Correlated with Immune Infiltration in Glioma

References

• Buckner JC, Brown PD, O’Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc. 2007;82(10):1271–1286. doi:10.4065/82.10.1271
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra0708126
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437. doi:10.1038/nm.3394
   PubMed Web of Science ®Google Scholar
• Quail DF, Bowman RL, Akkari L, et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016;352(6288):aad3018. doi:10.1126/science.aad3018
   PubMed Web of Science ®Google Scholar
• Gutmann DH. Microglia in the tumor microenvironment: taking their TOLL on glioma biology. Neuro Oncol. 2015;17(2):171–173. doi:10.1093/neuonc/nou346
   PubMed Web of Science ®Google Scholar
• Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610–622. doi:10.1038/nrn2175
   PubMed Web of Science ®Google Scholar
• Ye XZ, Xu SL, Xin YH, et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol. 2012;189(1):444–453. doi:10.4049/jimmunol.1103248
   PubMed Web of Science ®Google Scholar
• Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482(7385):339–346. doi:10.1038/nature10887
   PubMed Web of Science ®Google Scholar
• Lu C, Wei Y, Wang X, et al. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer. 2020;19(1):28. doi:10.1186/s12943-020-1137-5
   PubMed Web of Science ®Google Scholar
• Wu X, Wang Y, Yu T, et al. Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro Oncol. 2017;19(9):1195–1205. doi:10.1093/neuonc/nox017
   PubMed Web of Science ®Google Scholar
• Wu W, Yu T, Wu Y, Tian W, Zhang J, Wang Y. The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression. J Exp Clin Cancer Res. 2019;38(1):133. doi:10.1186/s13046-019-1132-0
   PubMed Web of Science ®Google Scholar
• He X, Sheng J, Yu W, Wang K, Zhu S, Liu Q. LncRNA MIR155HG promotes temozolomide resistance by activating the wnt/beta-catenin pathway via binding to PTBP1 in glioma. Cell Mol Neurobiol. 2021;41:1271–1284.
   PubMed Web of Science ®Google Scholar
• He Y, Ye Y, Tian W, Qiu H. A novel lncRNA panel related to ferroptosis, tumor progression, and microenvironment is a robust prognostic indicator for glioma patients. Front Cell Dev Biol. 2021;9:788451. doi:10.3389/fcell.2021.788451
   PubMed Web of Science ®Google Scholar
• Wang W, Li J, Lin F, Guo J, Zhao J. Identification of N(6)-methyladenosine-related lncRNAs for patients with primary glioblastoma. Neurosurg Rev. 2021;44(1):463–470. doi:10.1007/s10143-020-01238-x
   PubMed Web of Science ®Google Scholar
• Yu K, Yang H, Lv QL, et al. Construction of a competitive endogenous RNA network and analysis of potential regulatory axis targets in glioblastoma. Cancer Cell Int. 2021;21(1):102. doi:10.1186/s12935-021-01789-z
   PubMed Web of Science ®Google Scholar
• Cui W, Meng W, Zhao L, Cao H, Chi W, Wang B. TGF-β-induced long non-coding RNA MIR155HG promotes the progression and EMT of laryngeal squamous cell carcinoma by regulating the miR-155-5p/SOX10 axis. Int J Oncol. 2019;54(6):2005–2018. doi:10.3892/ijo.2019.4784
   PubMed Web of Science ®Google Scholar
• Qin Y, Liu X, Pan L, Zhou R, Zhang X. Long noncoding RNA MIR155HG facilitates pancreatic cancer progression through negative regulation of miR-802. J Cell Biochem. 2019;120(10):17926–17934. doi:10.1002/jcb.29060
   PubMed Web of Science ®Google Scholar
• Tao M, Zhou Y, Jin Y, Pu J. Blocking lncRNA MIR155HG/miR-155-5p/-3p inhibits proliferation, invasion and migration of clear cell renal cell carcinoma. Pathol Res Pract. 2020;216(2):152803. doi:10.1016/j.prp.2019.152803
   PubMed Web of Science ®Google Scholar
• Ren XY, Han YD, Lin Q. Long non-coding RNA MIR155HG knockdown suppresses cell proliferation, migration and invasion in NSCLC by upregulating TP53INP1 directly targeted by miR-155-3p and miR-155-5p. Eur Rev Med Pharmacol Sci. 2020;24(9):4822–4835. doi:10.26355/eurrev_202005_21171
   PubMed Web of Science ®Google Scholar
• Amin V, Harris RA, Onuchic V, et al. Epigenomic footprints across 111 reference epigenomes reveal tissue-specific epigenetic regulation of lincRNAs. Nat Commun. 2015;6:6370. doi:10.1038/ncomms7370
   PubMed Web of Science ®Google Scholar
• Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484–492. doi:10.1038/nrg3230
   PubMed Web of Science ®Google Scholar
• Heward JA, Lindsay MA. Long non-coding RNAs in the regulation of the immune response. Trends Immunol. 2014;35(9):408–419. doi:10.1016/j.it.2014.07.005
   PubMed Web of Science ®Google Scholar
• Flores-Concha M, Onate AA. Long non-coding RNAs in the regulation of the immune response and trained immunity. Front Genet. 2020;11:718. doi:10.3389/fgene.2020.00718
   PubMed Web of Science ®Google Scholar
• Carpenter S, Aiello D, Atianand MK, et al. A long noncoding RNA mediates both activation and repression of immune response genes. Science. 2013;341(6147):789–792. doi:10.1126/science.1240925
   PubMed Web of Science ®Google Scholar
• Chen S, Wang L, Fan J, et al. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res. 2015;75(3):519–531. doi:10.1158/0008-5472.CAN-14-2331
   PubMed Web of Science ®Google Scholar
• Zheng Z, Sun R, Zhao HJ, et al. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Mol Cancer. 2019;18(1):54. doi:10.1186/s12943-019-0977-3
   PubMed Web of Science ®Google Scholar
• Peng L, Chen Z, Chen Y, Wang X, Tang N. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Cancer Med. 2019;8(17):7161–7173. doi:10.1002/cam4.2583
   PubMed Web of Science ®Google Scholar
• Wu X, Hou P, Qiu Y, Wang Q, Lu X. Large-scale analysis reveals the specific clinical and immune features of DGCR5 in glioma. Onco Targets Ther. 2020;13:7531–7543. doi:10.2147/OTT.S257050
   PubMed Web of Science ®Google Scholar
• Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016;19(1):20–27. doi:10.1038/nn.4185
   PubMed Web of Science ®Google Scholar
• Prosniak M, Harshyne LA, Andrews DW, et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res. 2013;19(14):3776–3786. doi:10.1158/1078-0432.CCR-12-1940
   PubMed Web of Science ®Google Scholar
• Lu-Emerson C, Snuderl M, Kirkpatrick ND, et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013;15(8):1079–1087. doi:10.1093/neuonc/not082
   PubMed Web of Science ®Google Scholar
• Ma Q, Long W, Xing C, et al. Cancer stem cells and immunosuppressive microenvironment in glioma. Front Immunol. 2018;9:2924. doi:10.3389/fimmu.2018.02924
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61–73. doi:10.1016/j.immuni.2013.07.005
   PubMed Web of Science ®Google Scholar
• Woehrer A, Bauchet L, Barnholtz-Sloan JS. Glioblastoma survival: has it improved? Evidence from population-based studies. Curr Opin Neurol. 2014;27(6):666–674. doi:10.1097/WCO.0000000000000144
   PubMed Web of Science ®Google Scholar
• Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol. 2020;22(10):1425–1438. doi:10.1093/neuonc/noaa154
   PubMed Web of Science ®Google Scholar
• Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015;11(9):504–514. doi:10.1038/nrneurol.2015.139
   PubMed Web of Science ®Google Scholar
• Genoud V, Marinari E, Nikolaev SI, et al. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncoimmunology. 2018;7(12):e1501137. doi:10.1080/2162402X.2018.1501137
   PubMed Web of Science ®Google Scholar
• Zhu H, You Y, Shen Z, Shi L. EGFRvIII-CAR-T cells with PD-1 knockout have improved anti-glioma activity. Pathol Oncol Res. 2020;26(4):2135–2141. doi:10.1007/s12253-019-00759-1
   PubMed Web of Science ®Google Scholar
• Jia D, Lin W, Tang H, et al. Integrative analysis of DNA methylation and gene expression to identify key epigenetic genes in glioblastoma. Aging. 2019;11(15):5579–5592. doi:10.18632/aging.102139
   PubMedGoogle Scholar
• Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. Lancet. 2018;392(10149):777–786. doi:10.1016/S0140-6736(18)31268-6
   PubMed Web of Science ®Google Scholar
• Su J, Ma Q, Long W, et al. LCTL is a prognostic biomarker and correlates with stromal and immune infiltration in gliomas. Front Oncol. 2019;9:1083. doi:10.3389/fonc.2019.01083
   PubMed Web of Science ®Google Scholar
• Dong X, Deng Q, Nie X, et al. Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma. Exp Mol Pathol. 2015;98(2):192–199. doi:10.1016/j.yexmp.2015.01.013
   PubMed Web of Science ®Google Scholar
• Tian HP, Lun SM, Huang HJ, et al. DNA methylation affects the SP1-regulated transcription of FOXF2 in breast cancer cells. J Biol Chem. 2015;290(31):19173–19183. doi:10.1074/jbc.M114.636126
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Sadreddini S, Baradaran B, Aghebati-Maleki A, et al. Immune checkpoint blockade opens a new way to cancer immunotherapy. J Cell Physiol. 2019;234(6):8541–8549. doi:10.1002/jcp.27816
   PubMed Web of Science ®Google Scholar
• Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment. Cancer Lett. 2016;370(1):85–90. doi:10.1016/j.canlet.2015.10.009
   PubMed Web of Science ®Google Scholar
• Dongre A, Rashidian M, Reinhardt F, et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 2017;77(15):3982–3989. doi:10.1158/0008-5472.CAN-16-3292
   PubMed Web of Science ®Google Scholar
• Lou Y, Diao L, Cuentas ER, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res. 2016;22(14):3630–3642. doi:10.1158/1078-0432.CCR-15-1434
   PubMed Web of Science ®Google Scholar
• Mak MP, Tong P, Diao L, et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res. 2016;22(3):609–620. doi:10.1158/1078-0432.CCR-15-0876
   PubMed Web of Science ®Google Scholar
• Patel S, Alam A, Pant R, Chattopadhyay S. Wnt signaling and its significance within the tumor microenvironment: novel therapeutic insights. Front Immunol. 2019;10:2872. doi:10.3389/fimmu.2019.02872
   PubMed Web of Science ®Google Scholar
• Ruan Y, Ogana H, Gang E, Kim HN, Kim YM. Wnt signaling in the tumor microenvironment. Adv Exp Med Biol. 2021;1270:107–121.
   PubMed Web of Science ®Google Scholar